Effects of sustained ligustrazine on hemorrheology in patients with chronic pulmonary heart disease.
Before and after oral administration of sustained Ligustrazine, changes of hemorrheology and TXA2/PGI2 were evaluated in 16 patients with advanced chronic pulmonary heart disease. A decrease in whole blood and plasma viscosity, and reductions in hematocrit and fibrinogen were found after one course of treatment with sustained Ligustrazine. The mechanism of these effects may be related to improved modulation of imbalance of TXA2/PGI2 in patients with advanced chronic pulmonary heart disease.
Peng
W
W
Pulmonary Disease Research Laboratory, Tongji Hospital, Tongji Medical University, Wuhan.
Duan
S F
SF
Cui
L H
LH
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D001809:Blood Viscosity / Q000187:drug effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006333:Heart Failure / Q000209:etiology; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D011660:Pulmonary Heart Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D013929:Thromboxane B2 / Q000097:blood
D005343:Fibrinolytic Agents; D011719:Pyrazines; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C017953:tetramethylpyrazine